STAT3 and squamous cell carcinoma: This suggests that well-differentiated, keratinizing regions within squamous cell carcinomas may not be as effectively targeted with anti-EGFR therapies, although downstream effector proteins thought to be responsible for resistance, such as constitutive activation of STAT3, are not yet possible to track down in vivo.